These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 35038570)

  • 41. Effectiveness of subcutaneous implantable cardioverter-defibrillator testing in patients with hypertrophic cardiomyopathy.
    Maurizi N; Tanini I; Olivotto I; Amendola E; Limongelli G; Losi MA; Allocca G; Perego GB; Pieragnoli P; Ricciardi G; De Filippo P; Ferrari P; Quarta G; Viani S; Rapacciuolo A; Bongiorni MG; Cecchi F
    Int J Cardiol; 2017 Mar; 231():115-119. PubMed ID: 28073660
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and efficacy of anti-tachycardia pacing in patients with hypertrophic cardiomyopathy implanted with an ICD.
    Adduci C; Semprini L; Palano F; Musumeci MB; Volpe M; Autore C; Francia P
    Pacing Clin Electrophysiol; 2019 Jun; 42(6):610-616. PubMed ID: 30903669
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Postapproval Study of a Subcutaneous Implantable Cardioverter-Defibrillator System.
    Gold MR; El-Chami MF; Burke MC; Upadhyay GA; Niebauer MJ; Prutkin JM; Herre JM; Kutalek S; Dinerman JL; Knight BP; Leigh J; Lucas L; Carter N; Brisben AJ; Aasbo JD; Weiss R;
    J Am Coll Cardiol; 2023 Aug; 82(5):383-397. PubMed ID: 37495274
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A propensity matched case-control study comparing efficacy, safety and costs of the subcutaneous vs. transvenous implantable cardioverter defibrillator.
    Honarbakhsh S; Providencia R; Srinivasan N; Ahsan S; Lowe M; Rowland E; Hunter RJ; Finlay M; Segal O; Earley MJ; Chow A; Schilling RJ; Lambiase PD
    Int J Cardiol; 2017 Feb; 228():280-285. PubMed ID: 27865198
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Updated risk assessments for sudden cardiac death in hypertrophic cardiomyopathy patients with implantable cardioverter-defibrillator.
    Park YM
    Korean J Intern Med; 2023 Jan; 38(1):7-15. PubMed ID: 36353786
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Disease Severity and Exercise Testing Reduce Subcutaneous Implantable Cardioverter-Defibrillator Left Sternal ECG Screening Success in Hypertrophic Cardiomyopathy.
    Srinivasan NT; Patel KH; Qamar K; Taylor A; Bacà M; Providência R; Tome-Esteban M; Elliott PM; Lambiase PD
    Circ Arrhythm Electrophysiol; 2017 Apr; 10(4):. PubMed ID: 28408651
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prevalence of subcutaneous implantable cardioverter-defibrillator based on template ECG screening and ineligible surface ECG predicting factors in patients with hypertrophic cardiomyopathy in China.
    Guo L; Zhang M; Hu M; Wang B; Wang J; Zuo L; Yang W; Liu B; Liu L
    Heart Vessels; 2019 May; 34(5):851-859. PubMed ID: 30465278
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy.
    Maron BJ; Spirito P; Ackerman MJ; Casey SA; Semsarian C; Estes NA; Shannon KM; Ashley EA; Day SM; Pacileo G; Formisano F; Devoto E; Anastasakis A; Bos JM; Woo A; Autore C; Pass RH; Boriani G; Garberich RF; Almquist AK; Russell MW; Boni L; Berger S; Maron MS; Link MS
    J Am Coll Cardiol; 2013 Apr; 61(14):1527-35. PubMed ID: 23500286
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Implantable cardioverter-defibrillators for hypertrophic cardiomyopathy: The Times They Are a-Changin'.
    Francia P; Olivotto I; Lambiase PD; Autore C
    Europace; 2022 Oct; 24(9):1384-1394. PubMed ID: 34966939
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of the new risk prediction model (HCM Risk-SCD) and classic risk factors for sudden death in patients with hypertrophic cardiomyopathy and defibrillator.
    Ruiz-Salas A; García-Pinilla JM; Cabrera-Bueno F; Fernández-Pastor J; Peña-Hernández J; Medina-Palomo C; Barrera-Cordero A; De Teresa E; Alzueta J
    Europace; 2016 May; 18(5):773-7. PubMed ID: 25855675
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Implantable cardioverter-defibrillator therapy in hypertrophic cardiomyopathy: A SIMPLE substudy.
    Vamos M; Healey JS; Wang J; Connolly SJ; Mabo P; Van Erven L; Kautzner J; Glikson M; Neuzner J; O'Hara G; Vinolas X; Gadler F; Hohnloser SH
    Heart Rhythm; 2018 Mar; 15(3):386-392. PubMed ID: 29157723
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: systematic review and meta-analysis.
    Schinkel AF; Vriesendorp PA; Sijbrands EJ; Jordaens LJ; ten Cate FJ; Michels M
    Circ Heart Fail; 2012 Sep; 5(5):552-9. PubMed ID: 22821634
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Shock Without Wires: A Look at Subcutaneous Implantable Cardioverter-Defibrillator Compared to Transvenous Implantable Cardioverter-Defibrillator for Ventricular Arrhythmias.
    Raja J; Guice K; Oberoi M; Whitwell S; Asbeutah AA; Russell A; Khouzam RN
    Curr Probl Cardiol; 2022 Sep; 47(9):100927. PubMed ID: 34311985
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Implantable cardioverter-defibrillators in patients with hypertrophic cardiomyopathy -- dilemmas and difficulties.
    Przybylski A; Małecka L; Pytkowski M; Chojnowska L; Lewandowski M; Sterliński M; Maciag A; Ruzyłło W; Szwed H
    Kardiol Pol; 2005 Oct; 63(4):391-7; discussion 398. PubMed ID: 16273479
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators.
    Maron BJ; Casey SA; Olivotto I; Sherrid MV; Semsarian C; Autore C; Ahmed A; Boriani G; Francia P; Winters SL; Giudici M; Koulova A; Garberich R; Rowin EJ; Sears SF; Maron MS; Spirito P
    Circ Arrhythm Electrophysiol; 2018 Apr; 11(4):e005820. PubMed ID: 29625970
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Contemporary strategies for risk stratification and prevention of sudden death with the implantable defibrillator in hypertrophic cardiomyopathy.
    Maron BJ; Maron MS
    Heart Rhythm; 2016 May; 13(5):1155-1165. PubMed ID: 26749314
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy: patient outcomes, rate of appropriate and inappropriate interventions, and complications.
    Vriesendorp PA; Schinkel AF; Van Cleemput J; Willems R; Jordaens LJ; Theuns DA; van Slegtenhorst MA; de Ravel TJ; ten Cate FJ; Michels M
    Am Heart J; 2013 Sep; 166(3):496-502. PubMed ID: 24016499
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ventricular tachycardia/fibrillation early after defibrillator implantation in patients with hypertrophic cardiomyopathy is explained by a high-risk subgroup of patients.
    Alsheikh-Ali AA; Link MS; Semsarian C; Shen WK; Estes NA; Maron MS; Haas TS; Formisano F; Boriani G; Spirito P; Maron BJ
    Heart Rhythm; 2013 Feb; 10(2):214-8. PubMed ID: 23041573
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy.
    Lin G; Nishimura RA; Gersh BJ; Phil D; Ommen SR; Ackerman MJ; Brady PA
    Heart; 2009 May; 95(9):709-14. PubMed ID: 19282314
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Begley DA; Mohiddin SA; Tripodi D; Winkler JB; Fananapazir L
    Pacing Clin Electrophysiol; 2003 Sep; 26(9):1887-96. PubMed ID: 12930505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.